Price$0.27-0.01 (-3.04%)
02:30 PM07:45 PM
News · 26 weeks35+167%
2026-03-012026-08-23
Mix1690d
- SEC Filings9(56%)
- Other2(13%)
- Earnings2(13%)
- Insider1(6%)
- Dividends1(6%)
- Leadership1(6%)
Latest news
25 items- SECSEC Form DEF 14A filed by Accuray IncorporatedDEF 14A - ACCURAY INC (0001138723) (Filer)
- SECAmendment: SEC Form S-3/A filed by Accuray IncorporatedS-3/A - ACCURAY INC (0001138723) (Filer)
- PRAccuray Reports Fourth Quarter and Fiscal 2026 Financial ResultsMADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026. Key HighlightsThe Company's transformation plan delivered more than $20 million of cost and margin improvement during fiscal 2026, significantly exceeding the Company's original target of $12 million.The Company announced a comprehensive financing transaction with TCW Asset Management that strengthens liquidity, reduces leverage, provides relief for certain covenants through December 2027, and enhances financial flexibility to support long-term strategic ob
- SECAccuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECSEC Form PRE 14A filed by Accuray IncorporatedPRE 14A - ACCURAY INC (0001138723) (Filer)
- PRAccuray Advances Strategic Priorities Through Key Executive Leadership AppointmentsMADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth. As part of these efforts, Accuray has named Todd Brown to lead the company's newly created Enterprise Performance Optimization organization and has appointed Sofiane Laoussadi as Senior Vice President, Global Services & Solut
- SECAccuray Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 19, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 6917084.A live webcast of the call
- SECSEC Form S-3 filed by Accuray IncorporatedS-3 - ACCURAY INC (0001138723) (Filer)
- PRAccuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value CreationMADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental change in its business strategy, the rollout of differentiated technology, and continued transformation in how the company operates. This enables a renewed focus on its core strengths in innovation, sales, and service while continuing to emphasize operational rigor. Improved Financial PositionAccuray has entered into definitive agreement
- SECAccuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure8-K - ACCURAY INC (0001138723) (Filer)
- INSIDERSEC Form 4 filed by SVP, Chief Commercial Officer Miele Paul Michael4 - ACCURAY INC (0001138723) (Issuer)
- SECSEC Form SD filed by Accuray IncorporatedSD - ACCURAY INC (0001138723) (Filer)
- PRAccuray Incorporated Reports Inducement Award Under NASDAQ Listing RulesMADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer. As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the "Inducement Awar
- SECSEC Form S-8 filed by Accuray IncorporatedS-8 - ACCURAY INC (0001138723) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Accuray IncorporatedSCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)
- INSIDERSEC Form 4 filed by Large owner Tcw Group Inc4 - ACCURAY INC (0001138723) (Issuer)
- PRAccuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with CancerMADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newest collaboration will support clinical research, education and training, and the development of adaptive therapies that help empower medical care teams to co
- ANALYSTAccuray downgraded by BTIG ResearchBTIG Research downgraded Accuray from Buy to Neutral
- SECSEC Form 10-Q filed by Accuray Incorporated10-Q - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- SECAccuray Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCURAY INC (0001138723) (Filer)
- PRAccuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), c
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Accuray IncorporatedSCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)
ARAY FAQ
7 questionsWhat does Accuray Incorporated do?
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of...Where does ARAY stock trade?
Accuray Incorporated (ARAY) is listed on NASDAQ.What sector and industry is ARAY in?
Accuray Incorporated operates in the Health Care sector, Medical/Dental Instruments industry.When did Accuray Incorporated go public?
Accuray Incorporated (ARAY) completed its IPO in 2007.What are analysts saying about ARAY?
Accuray Incorporated has had 4 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2026-05-07. Recent price targets range from $750.00 to $900.00.What companies are similar to ARAY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ARAY side-by-side with any of them on Quantisnow.How can I track ARAY on Quantisnow?
Quantisnow aggregates Accuray Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARAY to receive live email and push alerts on every new disclosure.